Skip to content
Can psychedelic-assisted psychotherapy create a truly revolutionary paradigm shift in psychiatry?

Details
Date:
11/09/2021
Start Time:
3:00 pm
End Time:
15:35

Kelsey Ramsden, MBA

Board Member and Consulting Advisor, MINDCURE

Former CEO of MindCure and first woman to take a psychedelic drug research company public, Kelsey Ramsden is now consulting to psychedelic research companies who are thoughtfully creating their strate…

Natan Ponieman

Head of Psychedelics Content, Benzinga

Natan Ponieman is a writer, journalist and filmmaker covering the psychedelics space, as it intersects with finance, policy and science. Natan is Head of Psychedelics Content at Benzinga where he ser…

Jon Kostakopoulos

President & CEO

Jon was the first study participant of New York University’s clinical trial treating alcohol use disorder with psilocybin-assisted therapy. Jon credits psilocybin-assisted therapy with curing his alco…

Dr. Marvin S. Hausman, MD

Chairman of Nova Mentis' Scientific Advisory Board; Board Chairman & Chief Scientific Officer for Pilz Bioscience, Nova Mentis Life Science Corp.

Dr. Marvin S. Hausman is the Chief Medical Officer of Pilz Bioscience Corp., a wholly-owned subsidiary of Nova Mentis, and is leading their research and development efforts in medicinal psychedelics. …

Amy Emerson

CEO, MAPS Public Benefit Corporation, MAPS

Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3)…

Dr. Jeeshan Chowdhury, PhD

CEO, Journey Colab

Dr. Jeeshan Chowdhury studied at University of Alberta as an RBC Loran Scholar and Oxford as a Rhodes Scholar, earning an MSc in diagnostic imaging (Oxford) and an MD/PhD (University of Alberta). He …

Get Recordings Now!

Easily access the recordings for your favorite Wonderland sessions, allowing you to revisit the discussions and insights shared by our visionary speakers.

Buy Now